Incannex engages Procaps to manufacture IHL-42X soft-gel capsules in preparation for pivotal clinical trials

Clinical stage pharmaceutical development company, Incannex Healthcare Limited (ASX: IHL, ‘Incannex’ or the ‘Company’), is pleased to announce that it has engaged Procaps S.A. (‘Procaps’) to develop and manufacture IHL-42X soft gel capsules, the Company’s proprietary combination cannabinoid drug under development for the treatment of obstructive sleep apnoea (‘OSA’).
The soft gel capsules will be pharmaceutical-grade and used in pivotal phase 2, phase 3 and open label clinical trials. Procaps is also equipped to provide subsequent commercial manufacture at scale.